secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2021-08-06T23:59:59+00:00
Accession:  0001493152-21-018937
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 3.01, 3.02, 8.01, 4.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Therapeutics completes reverse merger with Decoy Biosystems; begins trading as INDP on Nasdaq
--------------------------------------------------------------------------------

- Decoy merger closed Aug 3, 2021; exchange ratio of 2.654353395 Indaptus shares per Decoy share.
- Post-merger 5,405,963 shares outstanding; Decoy shareholders own 65.6%, Intec Israel owns 34.4%.
- Company renamed Indaptus Therapeutics, now a pre-clinical biotech focused on cancer and viral immunotherapy.
- Board expanded to eight directors; Michael Newman appointed Chief Scientific Officer; CEO Meckler remains.
- Expected to dismiss PWC as auditor and engage Haskell & White for fiscal 2021 audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/0001493152-21-018937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315221018937/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-018937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer